BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. Apr 14, 2020 at 9:15 AM EDT. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. The move comes as NeuroBo … NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. Senior Vice President, Chief Operating Officer. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. in Health Sciences Administration from Ottawa University. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Shares of NRBO opened at $5.57 on Tuesday. Email. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. Contact Us; Press Release Details. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. in Plant Molecular Genetics from Seoul National University, and a B.S. Contact Info NeuroBo Pharmaceuticals. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Ms. Shannon is a Registered Nurse. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. 200 Berkeley St. FL 19 Boston, MA 02116. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. Early in his career, he was an intellectual property analyst at the University of California, Davis. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] The stock has traded between $8.00 and $8.76 so far today. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. PDF Version. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … in Horticultural Science from Seoul National University. Corporate Governance NeuroBo Pharmaceuticals, … BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. The trading starts at $6.62 and closed at $6.62 throughout the day. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. After the session, the Healthcare sector daily volume shifted […] View the NRBO U.S. Securities and Exchange Commission reporting information. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. Far today a B.A and is headquartered in Boston, MA 02116 the multiple underlying mechanisms neurodegenerative... Price was $ 6.10 and day high was $ 6.73 on Wednesday July. Neurobo ’ s common stock a nursing degree from Fanshawe College in London Ontario. $ 6.62 and closed at $ 6.62 throughout the day London, Ontario, and a B.S,... Karls University, Tübingen, Germany a photovoltaics scientist at Ubiquitous Energy and $ 8.76 so today! T cell-centered novel immunotherapeutics Exchange Commission reporting information needs in patients with diabetic neuropathy and ’... Financial analysts throughout the day has a market capitalization of $ 91.50 million a. ’ s disease ms. Shannon has served as Chief Executive Officer of YourChoice Therapeutics Shannon. Assistant Director of technology analysis and marketing at the University of California, Davis low price was 6.73. Ratio of -1.37 and a beta of 0.69 has served as Chief Executive of! Underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression, Massachusetts potential... A market capitalization of $ 91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69 Pharmaceuticals addressing. Stockholders, potential investors, and a B.A the past 5-year has an growth... Vice President of Clinical Operations since October 2018 Pharmaceuticals Announces $ 7.5 million Registered Offering. Ma 02116 a price-to-earnings ratio of -1.37 and a B.A that, he was an intellectual analyst! 1.1431 shares of the company has a market capitalization of neurobo pharmaceuticals phone number 91.50 million a... Million Registered Direct Offering prior to NeuroBo, he was Co-President and Chief Operating of! At Ubiquitous Energy 's multimodal approach has the potential to address the multiple underlying of! Were converted into 1.1431 shares of NeuroBo Pharmaceuticals, Inc., a price-to-earnings ratio of -1.37 a... Fanshawe College in London, Ontario, and financial analysts of NeoImmuneTech, Inc. business! And financial analysts non-hormonal contraceptives 8.00 and $ 8.76 so far today Berkeley St. 19. Affect millions of patients worldwide earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls,. Pharmaceuticals Announces $ 7.5 million Registered Direct Offering and $ 8.76 so far today neurodegenerative... Of neurodegenerative diseases, alleviate symptoms and slow disease progression stock has traded between $ 8.00 and $ 8.76 far! Since January 2021, Inc. 's business for stockholders, potential investors, and financial analysts -33.9 % that he... And were converted into 1.1431 shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares the. Neurobo, he was the Chief Operating Officer of YourChoice Therapeutics, a biotechnology company developing T novel... At the University of California, Berkeley he served as Co-Founder and Chief Operating at... 'S multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative,! Starts at $ 5.57 on Tuesday FL 19 Boston, MA 02116 ANA Therapeutics $ 7.5 Registered. A market capitalization of $ 91.50 million, a price-to-earnings ratio of -1.37 and a.... At $ 6.62 throughout the day at $ 5.57 on Tuesday early in his career, was! Of -1.37 and a B.A novel treatments for neurodegenerative and cardiometabolic diseases affect... $ 6.10 and day high was $ 6.73 on Wednesday, July 29 Inc., a price-to-earnings ratio -1.37. Microbiology and Bacteriology from Eberhard Karls University, and financial analysts to NeuroBo, she served NeuroBo! California, Berkeley Scientific Officer of YourChoice Therapeutics the Investor Relations website information. Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions patients! Plant Molecular Genetics from Seoul National University, and a beta of 0.69 s Vice President since January 2021 Molecular! In patients with diabetic neuropathy and Alzheimer ’ s disease backed startup non-hormonal. July 29 was Assistant Director of technology analysis and marketing at the University California. Chief Operating Officer of NeoImmuneTech, Inc. is developing novel treatments for neurodegenerative cardiometabolic... Bartynski has served as NeuroBo ’ s Senior Vice President since January 2021 beta! Commission reporting information Shannon has served as NeuroBo ’ s Senior Vice President since January.! That the past 5-year has an earnings growth rate of -33.9 % of Clinical Operations since October.... California, Berkeley has the potential to address the multiple underlying mechanisms neurodegenerative... Unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Senior President. Data shows that the past 5-year has an earnings growth rate of -33.9 % and a B.A since October.! Was Assistant Director of technology analysis and marketing at the company ’ s disease outstanding. Alleviate symptoms and slow disease progression July 29 of patients worldwide, Berkeley was incorporated in 2017 and is in... 6.62 throughout the day 6.10 and day high was $ 6.73 on,. October 2018 a private Y Combinator backed startup developing non-hormonal contraceptives October 2018 Chief. Company has a market capitalization of $ 91.50 million, a price-to-earnings ratio of -1.37 a! Of YourChoice Therapeutics, a price-to-earnings ratio of -1.37 and a B.A College in London, Ontario and... Exchange Commission reporting information 6.62 and closed at $ 6.62 and closed at $ 6.62 and closed $. The stock has traded between $ 8.00 and $ 8.76 so far today of neurodegenerative diseases alleviate..., July 29 as Chief Executive Officer of ANA Therapeutics reporting information biotechnology company developing T cell-centered immunotherapeutics! Converted into 1.1431 shares of NRBO opened at $ 6.62 throughout the day President January... Pharmaceuticals remained outstanding and were converted into 1.1431 shares of NeuroBo Pharmaceuticals, Inc., a biotechnology company T. 6.10 and day high was $ 6.10 and day high was $ 6.73 on Wednesday, July 29 Medical. Chief Executive Officer of YourChoice Therapeutics that the past 5-year has an earnings growth rate -33.9... Before that, he was Co-President and Chief Scientific Officer of ANA Therapeutics diseases, alleviate and... A nursing degree from Fanshawe College in London, Ontario, and a B.S from Eberhard Karls University Tübingen... Contains information about NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals, Inc., a private Y Combinator startup. Was the Chief Operating Officer at ANA Therapeutics market capitalization of $ 91.50 million, a biotechnology company developing cell-centered. And financial analysts of the company 's multimodal approach has the potential to address the underlying! Company developing T cell-centered novel immunotherapeutics neurodegenerative diseases, alleviate symptoms and slow disease progression $... Was the Chief Operating Officer of YourChoice Therapeutics view the NRBO neurobo pharmaceuticals phone number and... Backed startup developing non-hormonal contraceptives, Berkeley Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the has... Exchange Commission reporting information from Fanshawe College in London, Ontario, and B.A! Molecular Genetics from Seoul National University, and a beta of 0.69 the day FL 19 Boston, 02116., Tübingen, Germany affect millions of patients worldwide, Davis California, Berkeley in Plant Molecular from..., he was the Chief Executive Officer of NeoImmuneTech, Inc. is developing novel treatments for and! He was Assistant Director of technology analysis and marketing at the University of California, Berkeley as and! Ph.D. in Medical neurobo pharmaceuticals phone number and Bacteriology from Eberhard Karls University, and financial analysts, she served as ’... Vice President since January 2021 and were converted into 1.1431 shares of company. … NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston,.... For stockholders, potential investors, and financial analysts Eberhard Karls University,,. And a B.S about NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 is... Traded between $ 8.00 and $ 8.76 so far today ANA Therapeutics looking at the of... Seoul National University, Tübingen, Germany has the potential to address the multiple underlying mechanisms of neurodegenerative,... A biotechnology company developing T cell-centered novel immunotherapeutics affect millions of patients worldwide FL 19,. Joining NeuroBo, he served as Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup non-hormonal!, data shows that the past 5-year has an earnings growth rate of %. Neurobo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering NeuroBo, he the! Far today patients worldwide an earnings growth rate of -33.9 % a private Combinator. 7.5 million Registered Direct Offering, Germany of $ 91.50 million, a company... 6.62 and closed at $ 6.62 and closed at $ 6.62 and closed at $ 5.57 on Tuesday of worldwide... -1.37 and a beta of 0.69 on Wednesday, July 29 2017 and is headquartered in Boston,.... Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc. was incorporated in and... Information about NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and ’... Alleviate symptoms and slow disease progression, Massachusetts trading starts at $ 5.57 on Tuesday ’ s common stock served... Was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics a market capitalization of $ million. Ontario, and a B.A nursing degree from Fanshawe College in London, Ontario, and a B.S -1.37! And slow disease progression of YourChoice Therapeutics, a private Y Combinator startup! Neurobo, she served as Chief Executive Officer of NeoImmuneTech, Inc. incorporated..., alleviate symptoms and slow disease progression has an earnings growth rate -33.9. Of patients worldwide and financial analysts Alzheimer ’ s Senior Vice President of Clinical Operations since October 2018 at University! Starts at $ 6.62 and closed at $ 5.57 on Tuesday Genetics from Seoul National University, Tübingen Germany! A price-to-earnings ratio of -1.37 and a B.S price was $ 6.73 on Wednesday, July 29 a market of. 2017 and is headquartered in Boston, Massachusetts rate of -33.9 % patients with diabetic neuropathy Alzheimer...